Dyslipidemia

Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.

On Chen, MD, director of the Cardiac Intensive Care Unit and the Advanced Lipid Management Program at Stony Brook University, takes hosts Jorge Plutzky, MD, and Michael Farkouh, MD, on a deep dive into clinical processes at his institution and his perspective on some of the latest advances in lipid management.

Results of the Ocean(a)-DOSE trial, a phase 2 dose-finding study presented at AHA 22, suggests use of olpasiran dosed at 75 mg or higher every 12 weeks was associated with a reduction of Lp(a) among 95% of patients.

Viet Le, PA-C, discusses the results of a study examining characteristics and outcomes among pregnant statin users from EHR data recorded at Intermountain Healthcare medical centers.

Data from a phase 3 trial presented at AHA 22 suggests use of edoxaban could be a safe and effective method for reducing risk of thromboembolism in pediatric patients with cardiovascular disease considered to be at increased risk of thrombosis.

An analysis of the GWTG-Atrial Fibrillation Registry data suggests Black patients with AFib were 25% less likely to receive a prescription for oral anticoagulation at discharge and 27% less likely to receive a DOAC than their non-Hispanic White counterparts.

An analysis of data from a quality improvement initiative demonstrates the majority of patients continue their anticoagulant regimen beyond the guideline-directed 3 months following provoked VTE.

An analysis of electronic medical record data from more than 140k patients hospitalized at 185 medical centers in the US provides insight into associations between preexisting statin use and reduced risk of severe disease in COVID-19.

An analysis of claims data from a 7-year period provides insight into the rate of ischemic stroke or systemic embolism and bleeding events with 2 popular DOACs in people with atrial fibrillation and valvular heart disease.

The beneficial effect of intensive BP control on cardiovascular and all-cause mortality was attenuated during 4.5 years of post-trial after SPRINT.

An analysis of the CASCADE FH Registry provides insight into differences in patient characteristics and outcomes among those with homozygous familial hypercholesterolemia enrolled in the registry as children and those enrolled in the registry as adults.

Statins and their specific role have been the subject of debate for years. In this feature, 6 leading experts in cardiometabolic health share their perspectives on whether statins should be used in the sense of primordial prevention for ASCVD.

A meta-analysis of 48 randomized controlled trials provides clinicians with insight into the comparative efficacy profiles of multiple nonstatin LDL-lowering agents when added to maximally tolerated statin therapy.

Results of a CTT meta-analysis from ESC Congress 22 detail the excess risk of muscle symptoms observed with statin therapy from more than 20 clinical trials assessing statins against placebo or less intensive statin therapy.

The PANTHER study, which was a meta-analysis of 7 RCTs comparing P2Y12 inhibitor monotherapy against aspirin for secondary prevention in CAD, suggests use of P2Y12 inhibitor monotherapy was associated with a 12% reduction in risk of the primary composite endpoint, with a 23% relative reduction in risk of myocardial infarction.

A phase 2 dose-finding trial presented at ESC Congress 22 suggests the use of milvexian could reduce the risk of ischemic stroke by up to 30% without a major increase in the risk of bleeding events in certain doses.

Our cardiology month in review spotlights the most popular content from the past month. The top content from August 2022 includes new antithrombotic guidance from CHEST, USPSTF recommendation statement on statin use in primary prevention, and coverage of ESC 22, including DELIVER, TIME, and other late-breaking data.

A modeling study presented at ESC 2022 provides insight into the differences in potential benefits of statin therapy based on lifelong use, delayed initiation, and early discontinuation among patients across the spectrum of cardiovascular risk.

The USPSTF released a new recommendation statement on August 23 outlining the organization's stance on use of statins for primary prevention based on current available evidence, with recommendations made for those 40-75, 75 and older, and based on 10-year CVD risk.

An analysis of more than 25,000 years of patient data details a U-shaped association between HDL-C levels and cardiovascular risk among adult men with high blood pressure.

On August 11, the American College of Chest Physicians (CHEST) released 44 new evidence-based recommendations in their new guidelines for perioperative management of antithrombotic therapy, which were published with the intention of replacing the 2012 guidelines on the subject.

After US-based data suggested cost as an inhibiting factor of ticagrelor use in older patients with ACS, an analysis of use in Canada details considerable variation in between-hospital levels of ticargelor, with use ranging from 0% to 83.6% of patients.

An analysis of data from a single center in Switzerland from a 15-year period details the prevalence of undiagnosed major risk factors among patients admitted with acute ischemic stroke, suggesting 67.7% present with at least 1 undiagnosed risk factor.

Dr. Gregory Weiss provides perspective on a recent study detailing the risks of thrombosis observed with different COVID-19 vaccines among patients from a group of countries in Europe.

A retrospective analysis comparing statin users and nonusers details the significant declines in arterial stiffness progression among patients of high atherosclerotic risk based on statin use and adherence in a cohort of more than 5000 patients.